Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial

AIMS: In the HORIZONS trial, in-hospital treatment with bivalirudin reduced bleeding and mortality in primary percutaneous coronary intervention (PCI) compared with heparin and routine glycoprotein IIb/IIIa inhibitors (GPI). It is unknown whether this advantage of bivalirudin is observed in comparis...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeymer, Uwe, van 't Hof, Arnoud, Adgey, Jennifer, Nibbe, Lutz, Clemmensen, Peter, Cavallini, Claudio, ten Berg, Jurrien, Coste, Pierre, Huber, Kurt, Deliargyris, Efthymios N., Day, Jonathan, Bernstein, Debra, Goldstein, Patrick, Hamm, Christian, Steg, Philippe Gabriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
FASTTrack Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4169872/
https://www.ncbi.nlm.nih.gov/pubmed/24849104
http://dx.doi.org/10.1093/eurheartj/ehu214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4169872/
https://www.ncbi.nlm.nih.gov/pubmed/24849104
http://dx.doi.org/10.1093/eurheartj/ehu214

Ejemplares similares